Expertise in
22
conditions

Dr. Theodore S. Hong

Radiology
148 Chestnut Street, 
Needham, MA 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Expertise in
22
conditions
148 Chestnut Street, 
Needham, MA 

Overview

Theodore Hong is a Radiologist in Needham, Massachusetts. Dr. Hong is highly rated in 22 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 290 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Connecticut Health Center Campus

Residency

University of Wisconsin Hospitals and Clinics

Specialties

Radiology

Licenses

Radiology in MA

Board Certifications

American Board Of Radiology

Hospital Affiliations

Newton-Wellesley Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center-Needham
148 Chestnut Street, Needham, MA 02492
Other Locations
Beth Israel Deaconess Medical Center-Radiation Oncology
330 Brookline Avenue, Fnb25, Boston, MA 02215
Winchester Hospital Center for Cancer Care
Center For Cancer Care, 620 Washington St, Winchester, MA 01890

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer
A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer
Enrollment Status: Recruiting
Publish Date: November 14, 2025
Intervention Type: Radiation, Drug
Study Drugs: FOLFOX/ nal-IRI, Paclitaxel, Carboplatin
Study Phase: Phase 2
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
Enrollment Status: Recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Telomerase-specific Type 5 Adenovirus OBP-301
Study Phase: Phase 1
Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 12, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
PACER (Pancreatic AdenoCarcinoma With Electron Intraoperative Radiation Therapy): A Phase II Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
PACER (Pancreatic AdenoCarcinoma With Electron Intraoperative Radiation Therapy): A Phase II Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Enrollment Status: Completed
Publish Date: November 25, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Phase Ib/II Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Phase Ib/II Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Radiation, Drug
Study Drug: TAS-102
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: FOLFIRINOX, Losartan, Nivolumab
Study Phase: Phase 2
Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Drug, Radiation
Study Drugs: 5-fluorouracil, Mitomycin-C
Study Phase: Early Phase 1
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Radiation
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Enrollment Status: Unknown
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1
Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer
Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: May 28, 2021
Intervention Type: Procedure, Radiation, Drug
Study Drugs: FOLFIRINOX, Capecitabine
Study Phase: Phase 2
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: September 25, 2020
Intervention Type: Drug, Radiation
Study Drugs: FOLFIRINOX, Losartan
Study Phase: Phase 2
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Radiation
Study Phase: Phase 3
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
Enrollment Status: Withdrawn
Publish Date: July 08, 2019
Intervention Type: Other
Phase I Study of Chemoradiation With Midostaurin (PKC412) For Locally Advanced Rectal Cancer
Phase I Study of Chemoradiation With Midostaurin (PKC412) For Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 18 Less Clinical Trials

289 Total Publications

Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors.
Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 14, 2025
Similar Doctors
Expertise in
43
conditions
Dr. Edward Yang
Radiology
Expertise in
43
conditions
Dr. Edward Yang
Radiology

Department Of Radiology

300 Longwood Ave, 
Boston, MA 
 (0.2 miles away)
857-218-6424
Languages Spoken:
English
See accepted insurances

Edward Yang is a Radiologist in Boston, Massachusetts. Dr. Yang is highly rated in 43 conditions, according to our data. His top areas of expertise are Cortical Dysplasia, Agyria Pachygyria Polymicrogyria, Focal or Multifocal Malformations in Neuronal Migration, and Polymicrogyria.

Expertise in
8
conditions
Dr. Miriam Bredella
Radiology
Expertise in
8
conditions
Dr. Miriam Bredella
Radiology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-726-7717
Languages Spoken:
English
See accepted insurances

Miriam Bredella is a Radiologist in Boston, Massachusetts. Dr. Bredella is highly rated in 8 conditions, according to our data. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 1 (NF1), Sleeve Gastrectomy, and Gastric Bypass.

Irving D. Kaplan
Expertise in
12
conditions
Dr. Irving D. Kaplan
Radiology
Expertise in
12
conditions
Dr. Irving D. Kaplan
Radiology

Beth Israel Deaconess Medical Center

330 Brookline Avenue, Finard Basement, 
Boston, MA 
 (0.1 miles away)
617-667-2345
Languages Spoken:
English
See accepted insurances

Irving Kaplan is a Radiologist in Boston, Massachusetts. Dr. Kaplan is highly rated in 12 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, Mycosis Fungoides, and Prostatectomy.

Frequently Asked Questions about Dr. Theodore S. Hong

How do I make an appointment with Dr. Theodore S. Hong?

You can book an appointment with Dr. Theodore S. Hong by calling their office at 781-767-1923. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Theodore S. Hong a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Theodore S. Hong is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Theodore S. Hong specialize in?

While Dr. Theodore S. Hong is a Radiology, they have specific expertise in Pancreatic Cancer, Anal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiology.

Does Dr. Theodore S. Hong participate in research or clinical trials?

Yes. Dr. Theodore S. Hong has published 289 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Theodore S. Hong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Theodore S. Hong accept my insurance?

Dr. Theodore S. Hong accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 781-767-1923 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hong's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile